We describe a technique for estimating the mass of anti-DNA antibodies by immunonephelometry of serum immunoglobulins (IgG, IgA, 1gM) before and after adsorption onto DNA bound to agarose-polylysine columns. Sixteen patients with systemic lupus erythematosus and 16 age-and sex-matched controls were studied. Precision was determined for high. value (In 10 patients) and low-value (in nine controls) ranges for each of the immunoglobulins. Within-run CVs ranged from 3.0% (IgG, controls) 
im-

munonephelometry . complement component 3 (C3)
The use of immunoadsorbents to selectively remove immunoglobulin fractions directed against specific antigens offersa technique with great potentialfor measurement of these antibodies, a potential further strengthened by the highly sensitive nephelometric techniques now available for assay of imniunoglobulins Techniques used to measure anti-DNAab include radiometric binding assays (7) (8) (9) and nonisotopic immunoassays such as enzyme-linked immunosorbent assay (EU8A) (13) and fluorometry (14) . In none of these techniques is antibody quantified in terms of concentration (mass of immunoglobulin per unit volume of serum). Here we present details on the development of such a technique.
Materials and Methods
Principle and Protocol
In this method, immunoglobulins are assayed after passage of serum through a column containing Ag(lys) upon which DNA has been adsorbed (5). These measurements represent the amount of iminunoglobulins remaining after removal of anti-DNAab. On subtracting these values from those obtained by passage of serum through Ag(lys) columns containing no DNA (a "blank" or control column), the difference represents the amount of the individual immunoglobulin fractions that is bound to DNA.
The protocol, outlined in Figure 1 , is carried out by pipetting a quantity of undiluted serum into the columns and eluting the serum with acetate buffer (pH 4.5, 150 mmol/L) into a microvolumetric flask of greater capacity than the combined void volume (see Results) of the column plus the volume of serum added to the column, to yield a predetermined finaldilution of the serum (in this work we used a 10-fold dilution). Aliquots of these dilutions are then assayed nephelometrically for IgG, IgA, and 1gM. The concentration of immunoglobulin of each class binding to DNA is then calculated by subtracting the value obtained with the DNA-bearing column from that obtained with the blank column.
Serum Specimens
Serum was obtained from patients who fulfilled the criteria of the American Rheumatism Association for the Nonstandard abbreviations:anti-DNAab, antibodies to DNA; SLE, systemic lupus erythematosus; Ag(lys), agarose-poly-iAysine; ELISA, enzyme-linked immunosorbent assay; IgG, IgA, and 1gM, inununoglobulins class G, A, and M, respectively; BD, Blue Dextran"; DNAase, deoxyribonuclease I (EC 3.1.21.1); and PBS, phosphate-buffered saline. 
Reagents
Ag(lys) (beaded agarose, with covalently bound poly-Llysine) was from P-L Biochemicals, Milwaukee, WI 53205; DNA (from calf thymus) and DNAase (from bovine pancreas) were from Worthington Biochemicals, Freehold, NJ 07728; and Blue Dextran" was from Pharmacia Corp., Piscataway, NJ 08854. Buffer salts, from J. T. Baker Co., Phillipsburg, NJ 08865, were of reagent grade. Sodium citrate and citric acid (bothUSP grade) were from Mallinckrodt,Inc., Lexington, KY 40361. EDTA, the tetrazoliuni salt, was from Sigma Chemical Co., St. Louis, MO 63178.
Apparatus
Chromatographic columns were supplied by either P-L Biochemicals ("Redi-Cols", 2-mL bed volume) or Kontes Glass Works, Vineland, NJ 08360. The latter columns are made of plastic, have an inside diameter of 8 mm, include a porous plastic tip and ifiling funnel designed by the manufacturer for use with these columns, and were filled with Ag(lys) to a bed depth of 10 mm, yielding a bed volume of 0.5 mL. Stopcockswere alsoobtained from Kontes Glass Works and were fitted with 5-cm Teflon arterial cannulas ("Angiocath"; Deseret Pharmaceutical Co., Inc., Sandy, UT 84070), which served as the lower tip of the column. Microvolumetric flasks (1-mL capacity) were from SGA Scientific Inc., Bloomfield, NJ 07003. All fittings were of the standard Luer-Lok type.
Procedures
Void-volume measurements.
We measured the columns' void volumes by using Blue Dextran 2000 (BD), modified from the manufacturer's procedure. Because this material consists ofdextranbound to an anionic dye and the Ag(lys) columns are catiomc, it was first necessary to saturate the columns with BD. To do so,we passed a 2 g/L solution of BD in phosphate-buffered saline (PBS; pH 7.4, consisting of 150 mmol of NaCl and 15 mmol of phosphate per liter) through the columns until the absorbance readings at 625 nm of the influent and effluent were the same. Excess BD solution was then eluted and the columns were rinsed with PBS until the effluent demonstrated no absorbance at 625 nm. BD was then reintroduced intothe colunms and eluted according to the manufacturer's method. We collected 62-L fractions of the eluate and measured the absorbance of each at 625 nm.
Elution studies. In some cases, we attempted to elute the immunoglobulins from the columns for direct measurements. We used two systems for these studies.
In the first, the columns were incubated at room temperature (20-25 #{176}C) for 1 h with 1 mL of DNAase (2000 kUfL) solution containing Mg2, 10 mmol/L in acetate buffer (150 mmolfL, pH 4.5). The columns were drained and the effluent was inactivated with EDTA in a finalconcentration of 7.4 mmol/L.
In the secondelution system, 1 mL of citrate buffer (0.5 mol/L, pH 2.5) was added to the column and incubated at room temperature for 15 mm. The effluent was collected and dialyzed to equilibrium vs 6 L of PBS (24 h at 4#{176}C). Control sera were taken through identical procedures.
Rate immunonephelometric measurements of immunoglobulins. We measured IgG, IgA, and 1gM with an automated immunochemistry analyzer (Auto ICS II), using reagents provided by the manufacturer (Beckman Instruments, Inc., Fullerton, CA 92634). 
Miscellaneous materials and methods.
For the C. luciliae assay we used kits provided by Zeuss Scientific Corp., Raritan, NJ 08869, and viewed the slides by use of the optical system previously described (3). For spectrophotometry we used a double-beam spectrophotometer (Model 25, Beckman Instruments).
Dialysis tubing was obtained
from Union Carbide Corp.,Films/PackagingDiv.,Chicago, IL 60638.
Results
Analytical Variables
Void-volume measurement.
Void-volume measurements
are demonstrated in Figure 2 for the 0.5-mL columns as compared with the 2-mL columns previously described (5). The 0.5-mL columns have a void-volume of < 200 L, as compared with over 500 1tL for the 2-mL columns. Thus we used the 0.5-mL columns in conjunction with 1-mL volumetric flasks in the remainder of the experiments. This allows as little as 100 L of serum to be applied to the columns to obtain a final 10-fold dilution of serum. from Ag(lys),, columns. Six specimens were eluted from the column with either DNAase (two sera) or the citrate buffer (four sera) (10, 11). The analytical recovery is shown in Table 1 . Only one of the six eluates (thatfrom specimen E) was positive by theCrithidia assay.These data show that directelution and measurement is generally unreliable. For thisreason, in subsequent experimentation we used the differential or "indirect" protocol.
Precision. We evaluated the precision of our method ( Table 2) Table 5 . Although moderate amounts of immunoglobulin-binding DNA were observed, in fact, the corresponding percentages are small and within the range of the controls.
Correlationwith the Radiometric Binding Assay
Correlation of the data obtained by the present technique with data from the radiometric binding assay is shown in Figure 4 . Because of the highly skewed distribution of these data, we applied two nonparametric tests of correlation (7-9, 12, 13) Table 4 ed from an inimunoadsorbent column would be the prefera- Table 3 . (17) . Thus, parallel columns, as described in this paper, must be used to provide an appropriate blank.
SensitivIty and Linearity of the Present Method Compared with a Radlometric Binding Assay
The use of a control column (i.e., without DNA) largely overcomes the problem of nonspecific binding of antibodies that recognizesome determinant on the Ag(lys) support material.
The fact that the patient (even patients with marked hypergammaglobulinemia) and control groups had similar total immunoglobulin concentrations further strengthensthe evidence against the idea that nonspecific thatno real correlation exists between the data obtained by r n df thismethod and the radiometric binding data. either not proportional to the dilution or not detectable. Thus we suggest that the "true"limitof detection for IgG, IgA, and 1gM is in the range of 100-200 mg/L. Nevertheless, the sensitivity of the method appears to be adequate for differentiating SLE patients from control subjects. The linearity of the present method appears to be superior to that for the radiometric binding assay. Not unexpectedly, large and significant differences are observed in the DNA-binding proffles of the groups studied, i.e., SLE patients and age-and sex-matched controls. Another interesting finding also came to light: normal subjects have detectable DNA-binding. In other assays in which immunoglobulins are not measured, this phenomenon has been attributed to nonspecific binding, i.e., binding of DNA by other proteins (20) . However, we demonstrate here that measurable quantities of the immunoglobulins themselves are bound to the DNA on the columns.
The differences in 1gM concentrations in patients and controls were not significantly significant. While it is tempting to speculate that this represents some aspect of impaired imniunoregulation, it is more probable that this is a meth- In addition to providing quantitative data regarding DNA-binding immunoglobulins, this method potentially could be used to quantify complement binding by these antibodies, by adding normal human serum to the columns and measuring the third component (C3) of complement in the serum before and after application, analogous to the procedure for immunoglobulin measurements. Such studies, and the application of this method to SLE patients who do not demonstrate antibodies to DNA, are currently underway. In the case of the latter group, sites on chromatin (DNA-protein complexes) may serve as epitopes to which antibodies could attach. Previous work on cation-complexed DNA immunoadsorbents has demonstrated that this binding is largely coulombic (21) and, quite likely, lysine-bound DNA will provide antigenic determinants common to chromatin. This application is particularly promising because of the finding that tetrazolium-complexed DNA adsorbs antinuclear antibodies not directed against native DNA (3). 
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